Research programme: protein-tyrosine kinase receptor antagonists - BiovitrumAlternative Names: BVT I; BVT II
Latest Information Update: 18 Mar 2009
At a glance
- Originator Biovitrum
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 15 Jun 2008 Preclinical trials in Acute myeloid leukaemia in Sweden (unspecified route)